These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 19033694)

  • 21. Rituximab maintenance stretches progression-free survival in patients with indolent NHL.
    Oncology (Williston Park); 2004 Sep; 18(10):1316. PubMed ID: 15526836
    [No Abstract]   [Full Text] [Related]  

  • 22. The addition of radiotherapy to chemotherapy does not improve outcome of early stage Hodgkin's lymphoma patients: a retrospective long-term follow-up analysis of a regional Italian experience.
    Olcese F; Clavio M; Rossi E; Spriano M; Ballerini F; Canepa L; Pierri I; Aquino S; Varaldo R; Manna A; Secondo V; Racchi O; Balleari E; Orcioni GF; Carella AM; Ghio R; Gobbi M
    Ann Hematol; 2009 Sep; 88(9):855-61. PubMed ID: 19189105
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pre-emptive treatment with rituximab of molecular relapse after autologous stem cell transplantation in mantle cell lymphoma.
    Andersen NS; Pedersen LB; Laurell A; Elonen E; Kolstad A; Boesen AM; Pedersen LM; Lauritzsen GF; Ekanger R; Nilsson-Ehle H; Nordström M; Fredén S; Jerkeman M; Eriksson M; Väärt J; Malmer B; Geisler CH
    J Clin Oncol; 2009 Sep; 27(26):4365-70. PubMed ID: 19652064
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Results of little or no treatment for lymphocyte-predominant Hodgkin disease in children and adolescents.
    Murphy SB; Morgan ER; Katzenstein HM; Kletzel M
    J Pediatr Hematol Oncol; 2003 Sep; 25(9):684-7. PubMed ID: 12972802
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High dose methylprednisolone and rituximab is an effective therapy in advanced refractory chronic lymphocytic leukemia resistant to fludarabine therapy.
    Dungarwalla M; Evans SO; Riley U; Catovsky D; Dearden CE; Matutes E
    Haematologica; 2008 Mar; 93(3):475-6. PubMed ID: 18310545
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Optimizing the treatment of patients with rituximab-pretreated recurrent indolent non-Hodgkin lymphoma.
    Leonard JP; Gregory SA; Maloney DG; Vose JM; Younes A; Zelenetz AD
    Clin Adv Hematol Oncol; 2008 Jun; 6(6):437-45. PubMed ID: 18567989
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG).
    Schulz H; Rehwald U; Morschhauser F; Elter T; Driessen C; Rüdiger T; Borchmann P; Schnell R; Diehl V; Engert A; Reiser M
    Blood; 2008 Jan; 111(1):109-11. PubMed ID: 17938252
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rituximab in auto-immune haemolytic anaemia and immune thrombocytopenic purpura: a Belgian retrospective multicentric study.
    Dierickx D; Verhoef G; Van Hoof A; Mineur P; Roest A; Triffet A; Kentos A; Pierre P; Boulet D; Bries G; Lê PQ; Janssens A; Delannoy A
    J Intern Med; 2009 Nov; 266(5):484-91. PubMed ID: 19549092
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Effective combination chemotherapy with rituximab for acute lymphoblastic leukemia with bone relapse after bone marrow transplantation].
    Abe T; Kitajima T; Honma K; Kurasaki T; Okazuka K; Shibasaki Y; Momoi A; Kuroha T; Masuko M; Yagisawa K; Furukawa T; Toba K; Aizawa Y
    Rinsho Ketsueki; 2008 Nov; 49(11):1556-61. PubMed ID: 19047788
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sequential intensified conditioning and tapering of prophylactic immunosuppressants for graft-versus-host disease in allogeneic hematopoietic stem cell transplantation for refractory leukemia.
    Liu QF; Fan ZP; Zhang Y; Jiang ZJ; Wang CY; Xu D; Sun J; Xiao Y; Tan H
    Biol Blood Marrow Transplant; 2009 Nov; 15(11):1376-85. PubMed ID: 19822296
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multicenter randomized phase II study of weekly or twice-weekly bortezomib plus rituximab in patients with relapsed or refractory follicular or marginal-zone B-cell lymphoma.
    de Vos S; Goy A; Dakhil SR; Saleh MN; McLaughlin P; Belt R; Flowers CR; Knapp M; Hart L; Patel-Donnelly D; Glenn M; Gregory SA; Holladay C; Zhang T; Boral AL
    J Clin Oncol; 2009 Oct; 27(30):5023-30. PubMed ID: 19770386
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of relapsing polychondritis with rituximab: a retrospective study of nine patients.
    Leroux G; Costedoat-Chalumeau N; Brihaye B; Cohen-Bittan J; Amoura Z; Haroche J; Limal N; Bletry O; Piette JC
    Arthritis Rheum; 2009 May; 61(5):577-82. PubMed ID: 19405005
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Use of rituximab in combination with conventional chemotherapy for the treatment of non-Hodgkin's lymphoma of the head and neck.
    Manolopoulos L; Gomatos IP; Leandros E; Alevizos L; Georgiou N; Giotakis J; Ferekidis E
    In Vivo; 2009; 23(3):475-8. PubMed ID: 19454517
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Can Rituximab Improve the Outcome of Patients with Nodular Lymphocyte-Predominant Hodgkin's Lymphoma?
    Mocikova H; Pytlik R; Stepankova P; Michalka J; Markova J; Koren J; Buresova L; Raida L; Kral Z
    Acta Haematol; 2015; 134(3):187-92. PubMed ID: 26021284
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Absolute lymphocyte count predicts therapeutic efficacy of rituximab therapy in follicular lymphomas.
    Behl D; Ristow K; Markovic SN; Witzig TE; Habermann TM; Colgan JP; Inwards DJ; White WL; Ansell SM; Micallef IN; Johnston PB; Porrata LF
    Br J Haematol; 2007 Jun; 137(5):409-15. PubMed ID: 17433025
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lymphocyte-predominant Hodgkin lymphoma--clinical features and treatment outcomes from a 30-year experience.
    Jackson C; Sirohi B; Cunningham D; Horwich A; Thomas K; Wotherspoon A
    Ann Oncol; 2010 Oct; 21(10):2061-2068. PubMed ID: 20332141
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nodular lymphocyte predominant Hodgkin lymphoma.
    Lee AI; LaCasce AS
    Oncologist; 2009 Jul; 14(7):739-51. PubMed ID: 19605845
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Successful outcome of patients with relapsed/refractor Hodgkin lymphoma treated with high dose chemotherapy at the National Adult Bone Marrow Transplant Unit at St. James's Hospital.
    Bacon CL; Daly P; Sheane B; Conneally EC; Browne PV; McCann S; Ni Chongaile M; O'Brian DS; Mc Dermott R; Hollywood D; Wilson L; Vandenberghe E
    Ir Med J; 2009 Jan; 102(1):26-8. PubMed ID: 19284016
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Nodular lymphocyte-predominant Hodgkin lymphoma in children: clinical course, biology, and management].
    Gorde-Grosjean S; Guimard G; Lambilliotte A; Coulomb-Lhermine A; Montravers F; Landman-Parker J
    Bull Cancer; 2014 Sep; 101(9):881-90. PubMed ID: 25296072
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chemoimmunotherapy with low-dose fludarabine and cyclophosphamide and high dose rituximab in previously untreated patients with chronic lymphocytic leukemia.
    Foon KA; Boyiadzis M; Land SR; Marks S; Raptis A; Pietragallo L; Meisner D; Laman A; Sulecki M; Butchko A; Schaefer P; Lenzer D; Tarhini A
    J Clin Oncol; 2009 Feb; 27(4):498-503. PubMed ID: 19075274
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.